ATE364721T1 - Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden - Google Patents

Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden

Info

Publication number
ATE364721T1
ATE364721T1 AT00944977T AT00944977T ATE364721T1 AT E364721 T1 ATE364721 T1 AT E364721T1 AT 00944977 T AT00944977 T AT 00944977T AT 00944977 T AT00944977 T AT 00944977T AT E364721 T1 ATE364721 T1 AT E364721T1
Authority
AT
Austria
Prior art keywords
data set
profile data
calibrated
gene expression
expression profiles
Prior art date
Application number
AT00944977T
Other languages
German (de)
English (en)
Inventor
Victor Tryon
Michael Bevilacqua
Danute Bankaitis-Davis
John Cheronis
Original Assignee
Source Precision Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26839213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE364721(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Source Precision Medicine Inc filed Critical Source Precision Medicine Inc
Application granted granted Critical
Publication of ATE364721T1 publication Critical patent/ATE364721T1/de

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00944977T 1999-06-28 2000-06-28 Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden ATE364721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14154299P 1999-06-28 1999-06-28
US19552200P 2000-04-07 2000-04-07

Publications (1)

Publication Number Publication Date
ATE364721T1 true ATE364721T1 (de) 2007-07-15

Family

ID=26839213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00944977T ATE364721T1 (de) 1999-06-28 2000-06-28 Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden

Country Status (13)

Country Link
EP (1) EP1198585B1 (https=)
JP (1) JP2004528526A (https=)
KR (1) KR20020079364A (https=)
AT (1) ATE364721T1 (https=)
AU (1) AU784233B2 (https=)
CA (1) CA2378008A1 (https=)
CY (1) CY1107733T1 (https=)
DE (1) DE60035196T2 (https=)
DK (1) DK1198585T3 (https=)
ES (1) ES2290046T3 (https=)
IL (2) IL147349A0 (https=)
PT (1) PT1198585E (https=)
WO (1) WO2001025473A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
AUPR480901A0 (en) * 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
EP1392871A4 (en) * 2001-05-22 2006-04-19 Gene Logic Inc MODELING MOLECULAR TOXICITY
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2277991A1 (en) * 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
US7662594B2 (en) 2002-09-20 2010-02-16 New England Biolabs, Inc. Helicase-dependent amplification of RNA
JP4632788B2 (ja) 2002-09-20 2011-02-16 ニュー・イングランド・バイオラブズ・インコーポレイティッド 核酸のヘリカーゼ依存性増幅
AU2002952696A0 (en) * 2002-11-14 2002-11-28 Genomics Research Partners Pty Ltd Status determination
US7778782B1 (en) 2002-12-17 2010-08-17 Entelos, Inc. Peroxisome proliferation activated receptor alpha (PPARα) signatures
US7396645B1 (en) 2002-12-17 2008-07-08 Entelos, Inc. Cholestasis signature
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
US7422854B1 (en) 2002-12-20 2008-09-09 Entelos, Inc. Cholesterol reduction signature
US7519519B1 (en) 2002-12-20 2009-04-14 Entelos, Inc. Signature projection score
AU2003901196A0 (en) * 2003-03-17 2003-04-03 Commonwealth Scientific And Industrial Research Organisation Analysis method
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
JPWO2005087924A1 (ja) * 2004-02-18 2008-01-31 株式会社三重ティーエルオー Ｄｎａチップ並びに疾患関連遺伝子の抽出方法
EP2062981B1 (en) 2005-06-16 2013-09-25 Life Technologies Corporation Gene expression profiling for identification and monitoring of multiple sclerosis
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
AU2007254206A1 (en) * 2006-05-16 2007-11-29 Source Mdx Assessment of effect of an agent on a human biological condition using rodent gene expression panels
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2315858A2 (en) 2008-07-08 2011-05-04 Source Precision Medicine, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
NZ593854A (en) 2009-01-06 2013-02-22 Source Prec Medicine Inc D B A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
US9074248B1 (en) 2012-12-18 2015-07-07 Qiagen Gmbh Primers for helicase dependent amplification and their methods of use
CN103525926B (zh) * 2013-10-08 2016-03-23 浙江大学 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5922184A (en) * 1997-07-21 1999-07-13 Bio-Rad Laboratories, Inc. Computer-directed detection of paraproteins
EP0960214A4 (en) * 1996-12-06 2004-08-04 Urocor Inc Diagnosis of disease status on HAnd from mRNA profiles
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
WO1999011822A1 (en) * 1997-09-03 1999-03-11 Gene Logic Inc. Method for predicting prognosis and treatment response for genetically based abnormalities
US6461817B1 (en) * 1997-09-12 2002-10-08 The Public Health Research Institute Of The City Of New York Non-competitive co-amplification methods
EP1027456B1 (en) * 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs

Also Published As

Publication number Publication date
EP1198585B1 (en) 2007-06-13
AU784233B2 (en) 2006-02-23
AU5898500A (en) 2001-05-10
DK1198585T3 (da) 2007-10-15
JP2004528526A (ja) 2004-09-16
DE60035196T2 (de) 2008-02-21
KR20020079364A (ko) 2002-10-19
CY1107733T1 (el) 2013-04-18
PT1198585E (pt) 2007-09-20
IL147349A0 (en) 2002-08-14
EP1198585A1 (en) 2002-04-24
WO2001025473A9 (en) 2002-08-08
IL147349A (en) 2011-12-29
DE60035196D1 (de) 2007-07-26
CA2378008A1 (en) 2001-04-12
WO2001025473A1 (en) 2001-04-12
ES2290046T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
ATE364721T1 (de) Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden
ATE429511T1 (de) Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
DE69910007D1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
DE60040335D1 (de) Derivatisierte nukleinsäuren und deren verwendung
ATE540319T1 (de) Verfahren für die bestimmung von fk506
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
WO2008063414A3 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
ATE267267T1 (de) Verfahren zur quantitativen bestimmung der genexpression mit hilfe der multiplexen competitiven reversen-transkriptase polymerase kettenreaktion
WO2004113912A8 (en) System and method for determining a temperature during analysis of biological fluid
DE502004008216D1 (de) Vorrichtung und verfahren zur simultanen durchführung von blutgruppenbestimmung, serumgegenprobe und antikörpersuch-test
DE69632716D1 (de) Verfahren zur drogenuntersuchung
ATE245197T1 (de) Entwurf diskontinuierlicher sonden unter verwendung von hybritopemapping
ATE443264T1 (de) Verfahren zur verwendung von quantitativen lipidmetabolondaten
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
DE60129008D1 (de) Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten
EP1288647A3 (de) Spektroskopisches Testsystem auf Basis von Mikrokapillaren
ATE508201T1 (de) Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening
DE50110174D1 (de) Verfahren und testkit zum nachweis von analyten in einer probe
MXPA01006914A (es) Metodos para identificar combinaciones de entidades como terapeuticas.
MXPA05006804A (es) Identificacion, monitoreo y tratamiento de enfermedad infecciosa y caracterizacion de condiciones inflamatorias relacionadas con enfermedad infecciosa usando perfiles de expresion genica.
DE10346863A1 (de) On-Board-Kontrolle für Analyseelemente
JP2011123039A (ja) 遺伝的アルゴリズムを使用する濃度波形の解析法及び定量法
Martins et al. Internal validation of two new retrotransposons-based kits (InnoQuant® HY and InnoTyper® 21) at a forensic lab
ATE323282T1 (de) VERFAHREN ZUR BESTIMMUNG EINES ERHÖHTEN RISIKOS EINER FRAU, EIN FOETUS MIT DEM ßDOWN-SYNDROMß ZU TRAGEN
ATE403739T1 (de) Verfahren zur verwendung teilungsarretierter zellen in screening-assays

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198585

Country of ref document: EP